How quality of life data contribute to our understanding of cancer patients' experiences? A study of patients with lung cancer

Quality of Life Research

Volumn 12, Issue 2, 2003, Pages 157-166

  Montazeri, Ali ^a,d   Milroy, Robert ^b   Hole, David ^c   McEwen, James ^a   Gillis, Charles R ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

^c W of Scotland Cancer Survlnc Unit   (United Kingdom)

^d Iranian Institute for Health Sciences Research   (Iran)

Author keywords

EORTC QLQ C30; EORTC QLQ LC13; Lung cancer; Nottingham Health Profile (NHP); Quality of life

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; COUGHING; FEMALE; FOLLOW UP; GENERAL HOSPITAL; GEOGRAPHY; HUMAN; INTERVIEW; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL ASSESSMENT; MEDICAL INFORMATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; STANDARD;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SCOTLAND; SICKNESS IMPACT PROFILE;

EID: 0037369773     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022232624891     Document Type: Article

References (44)

1. International Association of Cancer Registries. Cancer incidence, mortality and prevalence world-wide (2000 estimates). www-dep.iarc.fr/globocan/globocan.html. (accessed 4 February 2002).
2. Carney DN. Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 1996; 23(Suppl 16): 71-75.
3. Tatcher N, Hopwood P, Anderson H. Improving quality of life in patients with non-small cell lung cancer: Research experience with gemcitabine. Eur J Cancer 1997; 33(Suppl 1): 8-11.
4. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997; 6: 225-236.
5. Giaccone G, Splinter TA, Debruyane C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133-2141.
6. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 577-580.
7. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. Br Med J 1998; 317: 771-775.
8. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer. A review of literature from 1970-1995. Chest 1998; 113: 467-481.
9. Joss RA, Alberto P, Hurny C, et al. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomised phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Ann Oncol 1995; 6: 41-48.
10. Joss RA, Bacchi M, Hurny C, et al. Early versus late alternating chemotherapy in small-cell lung cancer. Ann Oncol 1995; 6: 157-166.
11. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur J Cancer 1998; 34: 1036-1044.
12. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
13. Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does treatment make a difference? Cancer 1989; 63: 1271-1278.
14. Gower NH, Rudd RM, Ruiz de Elvira MCR, et al. Assessment of quality of life using daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. Ann Oncol 1995; 6: 575-580.
15. Kaasa S, Mastekaasa A, Thorud E. Toxicity, physical function, and everyday activity reported by patients with inoperable non-small cell lung cancer in a randomised trial: Chemotherapy versus radiotherapy. Acta Oncol 1988; 27: 343-349.
16. Sarna L. Women with lung cancer: Impact on quality of life. Qual Life Res 1993; 2: 13-22.
17. Hunt SM, Mckenna SP, McEwen J. The Nottingham Health Profile User's Manual. Manchester: Galen Research, 1993.
18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C-30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
19. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635-642.
20. Zubrod CG, Scheiderman MA, Frei E. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chro Dis 1960; 11: 7-33.
21. Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen: Aberdeen University Press, 1991.
22. Swinscow TDV. Statistics at Square One. London: British Medical Association, 1993.
23. Everitt BS. The Cambridge Dictionary of Statistics in the Medical Sciences. Cambridge: Cambridge University Press, 1995, 31-32.
24. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(Suppl 3): 178-189.
25. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24: 17-24.
26. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomised trial with quality of life as the primary outcome. Br J Cancer 2000; 83: 447-453.
27. Hopwood P. Quality of life assessment in chemotherapy trials for non-small cell lung cancer: Are theory and practice significantly different? Semin Oncol 1996; 23(Suppl 10) 60-64.
28. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 4: 1087-1100.
29. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
30. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support. J Clin Oncol 2000; 18: 395-404.
31. Harpole LH, Nolte KC, D'Amico TA, Crawford NJ, Harpole DH. Assessing lung cancer patient outcomes at point of service. Proc Am Soc Clin Oncol 2001: 20: 2817 (abstract).
32. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
33. Simmonds P. Managing patients with lung cancer. Br Med J 1999; 319: 527-528.
34. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 1999; 86: 1867-1876.
35. Choy H, Shyr Y, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for non-small cell lung carcinoma in the US. Cancer 2000; 88: 1336-1346.
36. Hopwood P, Stephens RJ. Depression in patients with lung cancer: Prevalence and risk factors derived from quality-of-life data. J Clin Oncol 2000; 18: 893-903.
37. Hopwood PH, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment. Br J Cancer 1995; 71: 633-636.
38. Bailey AJ, Parmar MK, Stephens RJ. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small cell lung cancer. J Clin Oncol 1998; 16: 3082-3093.
39. Moinpour CM. Measuring quality of life: An emerging science. Semin Oncol 1994; 21(Suppl 10): 48-63.
40. Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) 1: Survival and prognostic factors. Br J Cancer 1993; 68: 1150-1156.
41. Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) II: Quality of life. Br J Cancer 1993; 68: 1157-1166.
42. James LE, Gower NH, Rudd RM, et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor -prognosis small-cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1996; 73: 1563-1568.
43. MRC Lung Cancer Working Party. Randomised trial of four-drug vs. less intensive two-drug chemotherapy in palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996; 73: 406-413.
44. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: As an important prognostic factor. Lung Cancer 2001; 31: 233-240.